DUBLIN: Mycovia Pharmaceuticals has announced a strategic partnership with Gedeon Richter for the commercialisation and manufacture of VT-1161 for recurrent vulvovaginal candidiasis (RVVC) in Europe, Latin America, Australia, Russia and other CIS countries. This agreement follows the announcement by Mycovia earlier this year of a strategic partnership with Jiangsu Hengrui Medicine to develop and commercialise…